|
Phosphoproteomic analysis of matched primary breast cancer (BC) and lymph node (LN) metastases. |
|
|
No Relationships to Disclose |
|
|
Employment - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Theranostics Health |
Consulting or Advisory Role - Perthera |
Patents, Royalties, Other Intellectual Property - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Medfusion |
|
|
Leadership - Ceres Nanosciences; Perthera |
Stock and Other Ownership Interests - Ceres Nanosciences; D3D Inc.; Perthera |
Consulting or Advisory Role - Ceres Nanosciences; Perthera; Zymeworks |
Research Funding - Ceres Nanosciences (Inst); GlaxoSmithKline (Inst) |
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty |
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera |
|
|
Honoraria - Abbvie; Arno Therapeutics; AstraZeneca; Celgene; Eisai; Genentech/Roche; Lilly; Nektar; Novartis; Pfizer |
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Celgene; Eisai; Genentech/Roche; Lilly; Nektar; Novartis; Pfizer |
Travel, Accommodations, Expenses - Abbvie; Celgene; Lilly; Nektar; Novartis; Pfizer |